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Abstract 
Aim 
Urinary N-terminal B-type natriuretic peptide NTproBNP levels are associated with the 
development of retinopathy of prematurity (ROP) in infants <30 weeks gestation. The 
incidence of ROP in more mature infants who meet other ROP screening criteria is very low. 
We therefore aimed to test whether urinary NTproBNP predicted ROP development in these 
infants. 
Methods 
Prospective observational study in 151 UK infants ≥30+0 weeks gestation but also <32 
weeks gestation and/or <1501g, to test the hypothesis that urinary NTproBNP levels on day 
of life (DOL) 14 and 28 were able to predict ROP development.  
Results 
Urinary NTproBNP concentrations on day 14 and day 28 of life did not differ between 
infants with and without ROP (medians 144mcg/ml vs 128mcg/ml respectively, p=0.86 on 
DOL 14 and medians 117mcg/ml vs 94mcg/ml respectively, p=0.64 on DOL28).  
Conclusion  
The association previously shown for infants <30 completed weeks between urinary 
NTproBNP and development of ROP was not seen in more mature infants. Urinary 
NTproBNP does not appear helpful in rationalizing direct ophthalmoscopic screening for 
ROP  in more mature infants, and may suggest a difference in pathophysiology of ROP in this 
population.  
Key Notes 
1) Published data for infants <30 completed weeks gestation suggests that urinary 
NTproBNP levels might contribute to identifying infants at risk from retinopathy of 
prematurity (ROP)  
2) We showed that this is not true for more mature infants who still fulfil UK screening 
criteria 
3) This difference may imply different pathophysiology of ROP development in more 
mature infants 
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UK: United Kingdom 
 
 
 
 
 
Introduction  
Visual impairment as a result of retinopathy of prematurity (ROP) is potentially preventable 
by screening (1), but at present screening is largely dependent on direct ophthalmoscopy, 
which requires the availability of ophthalmologists willing and able to perform this. 
Although telemedicine and digital photography have improved access in some areas, costs, 
training expertise and other practicalities restrict universal screening (2-4).  This and the 
physical discomfort and instability caused to the infant (5), and distressing nature of the 
examination to the family, mean that non-invasive markers of ROP development have been 
sought, and algorithms generated to attempt to maximize the performance of features 
associated with ROP development to accurately predict this (6,7). To date, no ‘ideal’ 
biomarkers of ROP have been identified and sufficiently tested, but urinary B-type 
natriuretic peptide (BNP) shows promise (8). Proteolytic cleavage of a precursor protein 
yields biologically active BNP and an inert N-terminal fragment, NTproBNP (amino acids 1-
76). Measuring NTproBNP concentrations is routine in cardiac failure in children and 
neonates (9,10) and often available in routine health provision laboratories relatively 
cheaply. Concentrations of NTproBNP in blood parallel those in the urine, making non-
invasive measurement possible (11). In a single-center pilot study, we showed that urinary 
NTproBNP/creatinine ratios (UNBCR) in the first month were significantly elevated in 
preterm infants who developed severe ROP, compared to controls (8). To further assess the 
predictive power of urinary NTproBNP concentrations and UNBCR during the first month of 
life to allow early identification of  infants at high or low risk of severe ROP, we conducted a 
prospective observational study (REDEXAM, REDucing Eye EXAMinations in preterm infants) 
in neonatal intensive units in 8 European and Middle East countries (12).  
This second study showed a strong association between urinary NTproBNP measurements 
on day 14 and 28 of life and subsequent ROP development, in a cohort of 967 infants of 
≤29+6 weeks gestation (12). This is potentially important as this cheap, readily available test 
could help reduce or target direct ophthalmoscopy reducing either the number of 
individuals ever needing to be screened, or the number of screens undertaken in an 
individual, or both. 
Gerull et al (13) recently confirmed the low incidence of retinopathy of prematurity( ROP) in 
Switzerland in more mature infants than those included in our second study - those 
between 30+0 and 31+6 weeks gestation. There was a very low incidence of any ROP (1.7% 
(56/3222)) and severe or treated ROP (0.16% (5/3222)) and these authors called for a 
review of screening criteria. Given the relatively large numbers of more mature infants 
compared to very immature infants, and the low rate of ROP in these more mature infants, 
the utility of urinary NTproBNP to predict ROP development in more mature infants who still 
fulfil screening criteria, is important. We therefore tested the hypothesis that urinary 
NTproBNP in the first month of life, in infants ≥30+0 weeks fulfilling UK ROP screening 
criteria by virtue of gestation (<32 completed weeks) birth weight (<1501g) or both, would 
predict ROP development. To do this we applied the methodology of our previous study (14) 
to infants with gestations ≥30+0 weeks, born only in the UK. 
  
Methods 
 Study setting 
7 neonatal intensive care units in the United Kingdom participated between November 2013 
and May 2015. Ethical approval was obtained from Newcastle and North Tyneside 2 ethics 
committee. 
Patients and measurements 
Infants with a gestational age ≥30+0 completed weeks gestation and/or <32+0 or <1501g, 
alive at 10 days were eligible. Written informed parental consent was obtained. Urine was 
collected on DOL (day of life)14 and DOL28 (or as close as possible) by each center by their 
usual method (cotton wool balls or pads in the nappy, bags or clean catches by staff or 
parents at routine nappy changes) and stored at -80ºC until analysis. Urinary NTproBNP 
concentrations were determined at one laboratory on one site (Newcastle Upon Tyne, UK) 
in batches by standard hospital laboratory automated commercial chemiluminescent 
sandwich immunoassays (Roche Modula P E170 run on a cobas e 411 analyser) as described 
previously (8,15). Urines with a level lower than the limits of detection of the assay were 
attributed the lower level (50 mcg/l). We also recorded infant weight on DOL14 and DOL28. 
Proportional weight gain was calculated by dividing the gain of the infant’s weight since 
birth on DOL14 or DOL28, respectively, by birth weight. 
ROP outcomes 
ROP screening examinations were unaffected by study participation, undertaken by serial 
binocular indirect ophthalmoscopy and carried out by experienced local ophthalmologists 
according to local and national guidelines unaware of urinary NTproBNP concentrations 
(14). ROP was staged according to the International Classification of Retinopathy of 
Prematurity (16) and allocated treatment according to the Early Treatment for Retinopathy 
of Prematurity criteria  (17). 
Statistical analysis 
NTproBNP results for infants with known ROP outcome and at least one urinary NTproBNP 
concentration measured were analysed using SPSS 23.0 (SPSS Inc, Chicago, IL). As NTproBNP 
results and other variables lacked a normal distribution, data are presented as median and 
range. We assessed the strength of association between continuous variables by Spearman 
rank order coefficients.  Differences in the distribution of continuous variables were 
assessed by the Mann-Whitney U test.   
Results 
A total of 151 infants, 77 (51%) male, of median gestation 31.0 (range 30.0 – 37.0) weeks 
and median birth weight 1420g (range 640-2430g) participated, including 105 singletons, 39 
twins (some of whom had non-surviving siblings), one triplet set and one quad set.   
Five infants died before ROP screening was complete. Of surviving infants, 11 (7.5%) had any 
ROP: two (1.4%) stage 1, eight (5.5%) stage 2 and one (0.7%) stage 3 (zone 3 only). No infant 
was ever treated for ROP, and all ROP resolved.  
We found that ROP of any grade was restricted to infants ≤ 32+0 weeks gestational age 
(n=123). None of the more mature infants who entered the study had any signs of ROP. In 
contrast to the cohort <30+0 weeks, there were no significant differences between infants 
with ROP, as opposed to infants without ROP for proportional weight gain or urinary 
NTproBNP concentrations on day 14 and day 28 of life (Table 1) . Urinary NTproBNP 
concentrations were poorly associated with birthweight for this cohort (figure 1). 
Discussion 
Successfully identifying a non-invasive biomarker for development of ROP would have 
significant financial, family and infant benefits. Urinary NTproBNP appeared promising in 
pilot work (8), and in a larger population of relatively immature infants (<30+0 weeks 
gestation (12). However in the present study done in more mature infants who are still 
judged at risk of ROP by current screening criteria, a relationship between urinary 
NTproBNP and the development of ROP has not been demonstrated.  
Although this was a relatively small study of 151 infants, this cohort is larger than that in the 
original pilot study (n=136) where a correlation was seen between ROP development and 
urinary NTproBNP, and a correlation was previously seen in the less mature UK infants (12). 
It is still possible that a larger study would show a relationship, but any study will suffer 
from the impact of assessing any test for ROP in a very low incidence population.  
Little is known about the role of BNP in development of ROP. The lack of correlation 
between urinary NTproBNP levels and ROP in more mature infants could indicate different 
pathophysiology of either ROP development or BNP release in comparison to less mature 
infants. Equally, in the more immature population urinary NTproBNP may simply act as a 
proxy measure of ‘sickness’ related to immaturity which subsequently relates to risk of ROP 
development. In the more mature population, where ROP development is rare, ‘sickness’ 
may then influence BNP levels but not ROP development, causing the relationship to be lost. 
We did not collect more extensive clinical data to allow this hypothesis to be tested further 
in this study, but future studies could explore this possibility, as well as being larger. 
We conclude that in this UK cohort urinary NTproBNP based levels for risk factors for ROP 
established for more immature infants fail to identify infants of 30+0 weeks or more who 
might benefit from, or not require, screening ophthalmoscopy.  Differences in other 
morbidities or potentially different pathophysiology of ROP development in more mature 
infants may explain this loss of correlation.  
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Figure 1  
 
Relationship between NTproBNP and birth weight 
